Corbus Pharmaceuticals Holdings, Inc. (CRBP) NASDAQ

7.69

-0.0589(-0.76%)

Updated at July 03 10:25AM

Currency In USD

Corbus Pharmaceuticals Holdings, Inc.

Address

500 River Ridge Drive

Norwood, MA 02062

United States of America

Phone

617 963 0100

Sector

Healthcare

Industry

Biotechnology

Employees

28

First IPO Date

October 27, 2014

Key Executives

NameTitlePayYear Born
Dr. Yuval Cohen Ph.D.Chief Executive Officer & Director1.03M1975
Dr. Dominic Smethurst M.A., M.D.Chief Medical Officer500,6981975
Mr. Sean F. Moran CPA, M.B.A.Chief Financial Officer680,2421958
Dr. Ian HodgsonChief Operating Officer01973
Ms. Christina BertschVice President of Human Resources0N/A

Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.